Clinical guidelines for the treatment of patients with non-ST-segment elevation myocardial infarction (NSTEMI) recommend an invasive strategy with cardiac catheterization, revascularization when clinically appropriate, and initiation of dual antiplatelet therapy regardless of whether the patient receives revascularization. However, although patients with NSTEMI have a higher long-term mortality risk than patients with ST-segment elevation myocardial infarction (STEMI), they are often treated less aggressively; with those who have the highest ischemic risk often receiving the least aggressive treatment (the "treatment-risk paradox"). Here, using evidence gathered from across the world, we examine some reasons behind the suboptimal treatment of patients with NSTEMI, and recommend approaches to address this issue in order to improve the standard of healthcare for this group of patients. The challenges for the treatment of patients with NSTEMI can be categorized into four "P" factors that contribute to poor clinical outcomes: patient characteristics being heterogeneous;
| Disease burden of non-ST-segment elevation myocardial infarction
Non-ST-segment elevation myocardial infarction (NSTEMI) is the leading cause of emergency hospitalization for acute coronary syndrome (ACS) in Europe and North America. [1] [2] [3] [4] Although both patients with NSTEMI and ST-segment elevation myocardial infarction (STEMI) are at a high risk of recurrent cardiovascular events, patients with NSTEMI have higher long-term mortality and cardiovascular risk than those with STEMI. [5] [6] [7] [8] Furthermore, the proportion of patients with acute myocardial infarction (MI) who have NSTEMI is increasing relative to those with STEMI. [9] [10] [11] Results from the French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction (FAST-MI) and the Swedish Websystem for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry showed that the 6-month and 1-year mortality of patients with STEMI or NSTEMI have generally decreased since 1995. 11, 12 However, since 2010, there has been no improvement in the 6-month mortality of patients with NSTEMI, regardless of whether or not they received percutaneous coronary intervention (PCI); in striking contrast, mortality has continued to decline in patients with STEMI during this time. 11 
| Guideline recommendations for invasive and antiplatelet treatment of patients with NSTEMI
The standard of care for patients with NSTEMI at high ischemic risk is an early invasive strategy with cardiac catheterization within 24 hours of the onset of symptoms, with prompt revascularization using PCI or coronary artery bypass graft (CABG) surgery as clinically indicated. [13] [14] [15] Major international guidelines also recommend initiation of at least 12 months of dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 inhibitor (ticagrelor, prasugrel, or clopidogrel) in patients with NSTEMI who are managed with medical therapy and/or who are treated with revascularization (ie, irrespective of initial treatment strategy), unless there are previous or ongoing contraindications. [13] [14] [15] [16] [17] [18] Ticagrelor is recommended over clopidogrel for patients with NSTEMI, including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). Ticagrelor is contraindicated in patients with previous intracranial hemorrhage or ongoing bleeds. [13] [14] [15] [16] [17] [18] Prasugrel is recommended for patients with NSTEMI who have received angiography and are undergoing PCI. However, prasugrel is not recommended for patients in whom coronary anatomy is unknown and an indication for PCI is not clearly established; patients who are 75 years of age or older; or patients with a body weight of less than 60 kg. Prasugrel is contraindicated in patients with previous intracranial hemorrhage, previous ischemic stroke or transient ischemic attack, or ongoing bleeds. [13] [14] [15] [16] [17] [18] Clopidogrel is a less potent P2Y 12 inhibitor than ticagrelor and prasugrel; it is recommended for patients who cannot receive ticagrelor or prasugrel, or who require oral anticoagulation. [13] [14] [15] [16] [17] [18] Clinical risk scores, such as the DAPT score, can help guide decisions around whether to continue antiplatelet therapy beyond 1 year, by providing a risk-benefit ratio based on age, smoking status, comorbidity, and medical history. 19 For patients with NSTEMI who are elderly and have a high comorbidity burden, conservative treatment could be a reasonable approach. 16, 19 1.3 | Invasive strategy and P2Y 12 inhibitor treatment evidence for NSTEMI An early invasive strategy of cardiac catheterization has a central role in the management of patients with NSTEMI because it facilitates:
confirmation of the diagnosis of ACS related to obstructive epicardial coronary artery disease; identification of the culprit lesion(s); the establishment of the indication for revascularization using PCI or CABG; the stratification of the patient's short-and long-term ischemic risk. 15 Compared with a more conservative strategy, an early invasive strategy has been shown to improve clinical outcomes and reduce recurrent ACS episodes, subsequent rehospitalization, and revascularization. 15 A meta-analysis of seven randomized clinical trials including 8375 patients with NSTEMI showed that, vs. a conservative strategy, an early invasive strategy was associated with lower incidences of 2-year all-cause mortality (4.9% vs. 6.5%; risk ratio [RR]: 0.75; 95% confidence interval [CI]: 0.63-0.90; P = .001), 2-year nonfatal MI (7.6% vs. 9.1%; RR: 0.83; 95% CI: 0.72-0.96; P = .012), and 13-month rehospitalization for recurrent ACS (19.9% vs. 28.7%; RR: 0.69; 95% CI: 0.65-0.74; P = .0001). 20 A separate meta-analysis of individual patient data from 5467 patients across three randomized controlled trials with a 5-year follow-up period showed that, vs. a selective invasive strategy, a routine invasive strategy was associated with a lower risk of cardiovascular death or nonfatal MI (14.7% vs. 17.9%; hazard ratio [HR]: 0.81; 95% CI: 0.71-0.93; P = .002) and lower risk of MI (10.0% vs. 12.9%; HR: 0.77; 95% CI: 0.65-0.90; P = .001). 21 There was an absolute risk reduction of 2.0%, 3.8%, and 11.1% in low-, intermediate-, and high-risk patients receiving a routine invasive strategy, respectively. 21 Registry data from six Arabian Gulf countries showed that patients with NSTEMI managed with PCI and CABG had better outcomes than those treated conservatively. 22 Guideline-indicated treatment of patients with NSTEMI with potent P2Y 12 In TRITON-TIMI 38, prasugrel showed a reduction in the primary composite efficacy endpoint of cardiovascular death, MI, or stroke vs. clopidogrel in the NSTEMI patient subgroup (HR: 0.85; 95% CI: 0.73-0.97). 23, 24 Prasugrel was associated with increased non-CABG major bleeding compared with clopidogrel (HR: 1.40; 95% CI:
1.05-1.88). The PLATO study showed a reduction in the primary efficacy endpoint of cardiovascular death, MI, or stroke for ticagrelor vs. clopidogrel for the NSTEMI patient subgroup (HR: 0.83; 95% CI: 0.73-0.94), with no significant increase in major bleeding. 25, 26 Primary efficacy and safety endpoints from the two trials are summarized in superiority of ticagrelor to clopidogrel for the prevention of cardiovascular events in patients with NSTEMI. 27 
| Suboptimal treatment of patients with NSTEMI
Despite the above recommendations and findings, patients with NSTEMI often receive less aggressive secondary prevention treatment than patients with STEMI. 8, 28 Moreover, patients who have the highest ischemic risk often receive the least aggressive treatment, including both invasive and medical management; a phenomenon that has been termed the "treatment-risk paradox." [29] [30] [31] [32] Suboptimal treatment of patients with multiple ischemic risk factors was highlighted in the Pattern of Repeat Cardiovascular Events
During Follow-up After First Diagnosis Event-MI-2 (PRECLUDE-2) registry study. 33 Ischemic risk factors consisted of multivessel disease, diabetes mellitus, chronic kidney disease, prior MI, and age of at least 65 years. 33 Results from the PRECLUDE-2 study, which included invasively managed patients with MI, showed a higher ischemic risk compared with bleeding risk during a median follow-up of 3.6 years;
having five ischemic risk factors, compared with only one risk factor, was associated with a 5 to 9 times increased incidence of ischemic events and a 2 to 4 times increased incidence of major bleeding. 33 The incidence of ischemic events increased with increasing number of ischemic risk factors, highlighting an unmet need for additional preventive measures in these high-risk patients. 33 The challenges for the treatment of patients with NSTEMI can be categorized into four "P" factors that contribute to poor clinical outcomes in these patients: patient characteristics, physician guideline implementation, procedure availability, and policy within the healthcare system. Here, we will consider each in turn and suggest some solutions to address these challenges in order to improve the standard of healthcare for this group of patients.
| CHALLENGES FOR THE TREATMENT OF PATIENTS WITH NSTEMI

| Patient characteristics
Patients with NSTEMI present with more heterogeneous characteristics than patients with STEMI, with a wide variation in ischemic risk and comorbid conditions, making NSTEMI more challenging to diagnose and treat in these patients. 34 There is also heterogeneity in the demographics of NSTEMI patient populations across the world, as indicated by the variety of patient demographic data across different countries. [37] [38] [39] This heterogeneity could partly explain the variation in mortality of patients with cardiovascular disease between countries. 37, 38, 40 Furthermore, patients with NSTEMI are more likely to be older in age and have a higher rate of comorbidities, such as diabetes, impaired renal function, and lung disease, than patients with STEMI. 41, 42 These comorbidities contribute to a greater burden of coronary artery disease and an increased risk of cardiovascular events for patients with NSTEMI, and therefore lead to increased long-term mortality. 5, 15 The wide variation in risk in patients with NSTEMI affects treatment decisions. Some patients are considered at too low risk of recurrent cardiovascular events to warrant an invasive strategy, whereas others are regarded as "too sick" to undergo coronary angiography and/or subsequent revascularization because of advanced age or severe comorbidities. 43 Figure 1 shows the benefit of invasive management vs. medical management on the survival of patients with NSTEMI.
Diagnosis of NSTEMI is also less straightforward than that of STEMI, which can be identified rapidly based on an electrocardiogram (ECG) measurement. The identification of patients with NSTEMI is often delayed owing to the frequent lack of definitive ECG changes and uncertainty about the definition of NSTEMI with regard to elevated cardiac troponin levels. 42 Implementation of high-sensitivity cardiac troponin assays will lead to an increase in the diagnosis of NSTEMI. 44 Age, sex, comorbidities, and in-hospital management strategies (eg, PCI or medical management) may also influence decisions in patients with NSTEMI regarding prescription at discharge. 28 43 Abbreviation: CAG, coronary angiography in these patients, which contributes to the suboptimal use of treatments and is suggestive of barriers to guideline implementation. 31, 41 In the ACS II Canadian registry, the most common reason for not choosing an invasive treatment strategy in patients with NSTEMI was an underestimation of ischemic risk by physicians, even though a large proportion of these patients were at intermediate to high risk according to their Thrombolysis in Myocardial Infarction (TIMI) risk score. 46, 47 Results from the registry also showed weak correlations between risk assessment by physicians and TIMI and Global Registry of Acute Coronary Events (GRACE) risk scores, 48 which are recommended for guiding treatment decisions for patients with NSTEMI in international guidelines. 13, 15 Objective risk assessment using the GRACE risk score provided superior risk discrimination to physician-perceived risk for 6-month mortality in patients with ACS in the Perceived Risk of Ischemic and Bleeding Events in Acute Coronary Syndrome Patients (PREDICT) study. 49 Here, physicians were shown to overestimate the risk of 6-month mortality among patients with a low GRACE score and underestimate risk among those with a high GRACE score, consistent with the treatment-risk paradox. 49 Patients with NSTEMI at high ischemic risk were also not treated optimally in the Myocardial Ischaemia National Audit Project (MINAP) registry, in which the use of guideline-indicated care for patients with NSTEMI decreased with increasing GRACE risk score, even though optimal guideline-indicated care was associated with greater survival gains for high-risk patients. 31 Adherence to guideline recommendations for the management of 51 Furthermore, data from national registries have indicated that patients with NSTEMI are more likely to receive clopidogrel than the potent P2Y 12 inhibitors, 29, 52, 53 which are generally preferentially recommended in international guidelines. 13, [15] [16] [17] There is also evidence to suggest that patients with NSTEMI may be less likely to be treated in academic medical centers than patients with STEMI, and therefore less likely to be directed to larger hospitals with catheterization laboratories; indicating some degree of referral bias toward patients with STEMI. 42 The risk may be underestimated by physicians based on the intensity of treatment the patients are receiving and the advanced age of the patient, despite evidence that an early intensive strategy in the eldest patients with NSTEMI is associated with the greatest reduction in 1-year mortality. [47] [48] [49] 54 Physicians' and/or patients' concerns about the risk of complications with an invasive strategy may also affect the implementation of guideline-indicated treatment. Furthermore, physicians may attribute mortality risk to comorbidities rather than the MI itself, even though evidence suggests that patients with NSTEMI have an increased risk of death beyond what can be explained by comorbidities. 41 Together, this evidence suggests that guidelines on risk stratification in patients with NSTEMI are insufficiently implemented, which may partly explain why the treatment of patients with NSTEMI is suboptimal. 28 2.3 | Procedure availability and policy within the healthcare system
Optimal guideline-indicated treatment of patients with NSTEMI is also affected by the availability of procedures, as well as governmental and hospital policies. Several studies have demonstrated wide geographical variation in the use of guideline-indicated treatments for patients with NSTEMI, which is linked to hospital and geographical characteristics. 30, [55] [56] [57] In the SNAPSHOT ACS study, assessing patients with chest pain admitted to hospitals in Australia and New Zealand, the proportion of patients with NSTEMI who were given a coronary angiogram varied from 56.5% to 68.9% across health jurisdictions, whereas the proportion of patients with STEMI/left bundle branch block given a coronary angiogram ranged from 81.1% to 100%. 30 Registry data from Arabian Gulf countries (Saudi Arabia, Bahrain, Qatar, Oman, United Arab Emirates, and Yemen) showed that only 26.8% of patients with NSTEMI received coronary angiography and 21.9% received revascularization with either PCI or CABG. 22 The rate of conservative management varied according to the country, and the relatively low rate of invasive management may be explained by the fact that fewer than half of the hospitals in the registry had an on-site catheterization laboratory. 22 Access to hospitals with catheterization was associated with reduced recurrent adverse cardiovascular events in patients with ACS. 58 A study using the Malaysian National Cardiovascular Disease Database-ACS (NCVD-ACS) registry showed geographical variations in prescribing rates for secondary preventive medications in patients with NSTEMI. 57 For example, patients in East Malaysia were less likely to be prescribed P2Y 12 inhibitors or aspirin than patients in the Western region of the Malaysian Peninsular. 57 In China, a nationwide database study that included 1055 tertiary hospitals showed an in-hospital mortality of 3.6% and a PCI utilization rate of 37.2% in patients with NSTEMI (corresponding rates in patients with STEMI were 5.1% and 47.8%, respectively). 55 The study identified wide variations in the rates of in-hospital mortality across geographical regions, and the rates were significantly lower in patients who received PCI than in those who did not. 55 Geographical variation in care may be due to the lack of availability of cardiologists, catheterization laboratories, and medical treatments in rural areas compared with urban areas. 60 For example, a study assessing outcomes in patients with acute MI in New South Wales, Australia, showed that patients with NSTEMI presenting to a rural hospital were 70% less likely to undergo cardiac revascularization than patients presenting to an urban hospital. 61 Geographical variation in care may also be affected by the financial burden of different P2Y 12 inhibitors to patients worldwide. Prasugrel and ticagrelor are generally more expensive than clopidogrel, which is no longer patented. Decision-analytical modeling in patients with ACS shows ticagrelor to be cost effective compared with generic clopidogrel across different countries and public healthcare systems, including in Sweden, the United Kingdom, Germany, and Brazil. 62 Costeffectiveness of ticagrelor compared with clopidogrel has also been shown from the China, Singapore, Thailand, and Vietnam healthcare perspectives. [63] [64] [65] [66] The implications of the mode of patient presentation to hospitals (ie, via emergency medical services [EMS] vs. self-presentation) were investigated in a study of patients with NSTEMI admitted to a welldefined metropolitan healthcare region in Edmonton, Alberta, Canada, over 3 months in 2008. 67 Of the 263 patients included in the study, 78.3% underwent cardiac catheterization, with lower utilization in the EMS group (60.2%) than the self-presenting group (88.2%; P < .001). 67 There was a significantly lower rate of cardiac catheterization in the patients with a high GRACE risk score (P < .001), which was especially apparent in patients who presented by EMS. 67 Catheterization rates in community hospitals (84.4%) were higher than those in PCI centers (71.9%; P = .014) even though patients admitted to PCI centers had an overall higher GRACE risk score. 67 Aside from differences in the availability of specialist services, variation in healthcare for patients with NSTEMI across hospitals could also be due to differences in: the number of hospital admis- 68 and TIMI (https://www.mdcalc.com/timi-risk-score-uanstemi) 69 risk scoring systems have undergone extensive validation and are recommended in international guidelines for guiding treatment decisions for patients with NSTEMI, 13, 15 and should be utilized by physicians ( Table 2 ). Use of the CRUSADE score (http://www. crusadebleedingscore.org/) 70 may also be considered in patients undergoing coronary angiography to quantify bleeding risk ( Table 2) . 15 Accurate risk estimation should help address the underestimation of risk in patients with NSTEMI. However, improving guideline implementation and adherence are key to overcoming the problem and optimizing treatment for these patients. We encourage the development of guidelines and hospital protocols that include quality assessment measures for assessing clinical uptake of guidelineindicated care. Quality measures should encourage optimal evidence-based treatment. For example, they need to specify which antiplatelet agents should be used rather than only the length of treatment. An example of a quality measure could be that "at least 75% of patients with a GRACE score above 140 must be treated with a potent P2Y 12 inhibitor, unless contraindicated." Good reasons need to be provided by physicians for failing to treat patients with a potent P2Y 12 inhibitor. For example, for patients with a GRACE score of 100 to 130, the use of these treatments might be dependent on the availability of resources. Importantly, the development of guidelines and protocols need to be supported with advocacy for their use, and national registries should be used in order to monitor the progress of improving healthcare for patients with NSTEMI. We recommend consulting the quality indicators recommended by Schiele et al, 71 which are included in 
T A B L E 3 Summary of the quality indicators: definitions and support from guidelines
Domain of care Quality indicator Support from ESC guidelines
Main QI: The center should be part of a Network Organization with written protocols for rapid and efficient management covering the following points • Single emergency phone number for the patient to be connected to a medical system for triage • Pre-hospital interpretation of ECG for diagnosis and decision for immediate transfer to a center with catheterization laboratory facilities, bypassing the Emergency Department • Pre-hospital activation of the catheterization laboratory Secondary QI (1): routine assessment of relevant times for the reperfusion process in STEMI patients (ie, times from "call to first medical contact," "first medical contact to door," "door to arterial access" and "door-in door-out" for centers without a catheterization laboratory on site) Secondary QI (2) indicators had a significant inverse association with 30-day mortality (all P < .001), suggesting that quality indicators have the potential to improve patient healthcare and reduce varied mortality from acute MI (Figure 2) .
Guidelines and hospital protocols should emphasize the importance of documenting patient history, which could affect NSTEMI diagnosis, and of regularly assessing the risks and benefits of therapies to suit the patient's clinical status, which may change over time. 54 Furthermore, guidelines and protocols should include guidance on how to manage patients with dyspnea because some physicians are concerned about dyspnea related to ticagrelor use in their patients, given that dyspnea is more frequently reported in patients with ACS prescribed ticagrelor compared with clopidogrel. 73, 74 The incidence of dyspnea in a realworld setting has been shown to be greater than that reported in clinical trials and may lead to higher rates of ticagrelor discontinuation. 74 However, given that there is evidence to suggest that dyspnea can resolve during inhibitor use, only in the case of persistent ticagrelor-related dyspnea should drug discontinuation be considered. 73 There is potential for reducing the impact of geographical variation could be a reasonable approach to improve treatment outcomes for patients with NSTEMI, which could be facilitated by existing regional platforms for the management of patients with STEMI. 67 
| CONCLUSIONS
Patients with NSTEMI have a higher long-term mortality risk than patients with STEMI but are often treated less aggressively, with those who have the highest ischemic risk often receiving the least aggressive treatment (the "treatment-risk paradox"). The suboptimal treatment of patients with NSTEMI can be explained by the heterogeneity of patient characteristics, an underestimation of the high ischemic risk compared with bleeding risk by physicians, procedure availability, and policy. To address these challenges, potential approaches include: developing guidelines and protocols that include rigorous definitions of NSTEMI, risk assessment, and integrated quality assessment measures; providing education to physicians on the management of long-term cardiovascular risk in patients with NSTEMI; and making stents and antiplatelet therapies more accessible to patients.
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